Xencor(NASDAQ) XNCR

Xencor, Inc. designs smart proteins to help the body fight cancer. These engineered treatments aim to attack sick cells. The company works with partners to get medicines to patients.

Engineering New Ways to Heal

• Oncology Programs: Experimental antibodies like XmAb819 that aim to kill tumor cells in kidney and ovarian cancers.
• Autoimmune Disease Programs: Therapies such as XmAb942 designed to treat inflammatory conditions like ulcerative colitis and Crohn's disease.
• Technology Licensing: Access to protein engineering platforms provided to partners who create their own proprietary drugs.
• Product Licenses: Rights granted to companies for developed treatments like the blood cancer drug Monjuvi.

Strategic Moves and Partnerships

• Entered a $105.0 million settlement with Alexion in July 2026 to resolve a dispute over royalty payments in the U.S.
• Advanced XmAb942 into a Phase 2b study for ulcerative colitis in the third quarter of 2025.
• Initiated a first-in-human clinical study of XmAb412 in the third quarter of 2026 to target inflammatory pathways.
• Received a $10.0 million milestone payment from Zenas in the second quarter of 2026 following a regulatory submission.

Why Their Technology Is Different

Xencor uses its proprietary XmAb platforms to change the structure of antibodies. This allows drugs to last longer in the body. The company also licenses this technology to partners to generate royalty income.

A Look at the Numbers

• Total revenue was $51.2 million for the three-month period ended June 30, 2026.
• Royalty revenue was $41.2 million for the three-month period ended June 30, 2026.
• Research and development expenses were $136.6 million for the six-month period ended June 30, 2026.
• Cash, cash equivalents, and marketable debt securities reached $486.4 million as of June 30, 2026.
• Operating loss was $114.9 million for the six-month period ended June 30, 2026.

The Bottom Line

Xencor has evolved from a research firm into a developer with multiple streams of royalty income from approved drugs. Its strategy of balancing internal discovery with partnerships helps fund its long-term medical pipeline.